Cogent Biosciences, Inc. COGT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$97.35M+5.0% | -$102.49M-26.6% | -$80.93M-10.1% | -$73.53M-2.1% | -$71.99M-6.0% | ||
| $626K-0.3% | $628K-2.0% | $641K-2.1% | $655K+2.3% | $640K+2.4% | ||
| $16.91M+7.3% | $15.75M+48.5% | $10.6M+9.1% | $9.72M-2.9% | $10.01M+0.3% | ||
| -$86.88M-9.8% | -$79.11M-23.1% | -$64.29M-17.9% | -$54.54M+18.0% | -$66.51M-9.8% | ||
| $449K-44.6% | $811K+1,148% | $65K-50.4% | $131K-76.1% | $547K+629% | ||
| -$36.46M+88.7% | -$322.77M-108% | -$155.05M-1,840% | $8.91M-87.2% | $69.38M+12.5% | ||
| —— | $13.66M0.0% | $13.66M0.0% | $13.66M0.0% | $13.66M— | ||
| $52.54M-91.1% | $588.67M+171% | $217.37M+360% | $47.23M+89.1% | $24.97M+95,938% | ||
| -$70.8M-138% | $186.8M— | $0-100% | $1.6M-94.3% | $27.84M+2,386% | ||
| -$87.33M-9.3% | -$79.92M-24.2% | -$64.35M-17.7% | -$54.67M+18.5% | -$67.06M-10.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Cogent Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.